Table 1.

Discontinuation rates in the long-term follow-up of COMFORT-I and COMFORT-II trials

	COMFORT-I		COMFORT-II
	Placebo (N)	Ruxolitinib (N)	Ruxolitinib (N)	Best available therapy (N)
Subjects	154	155	146	73
Discontinued*
Before cross over	40 (25.9%)			28 (38.4%)
After cross over	36 (23.4%)			23 (31.5%)
Total discontinuation	76 (49.3%)	55 (35.5%)	80 (54.8%)	51 (69.9%)

Notes:

^*In COMFORT I, the follow-up was at a median time of 2 years; in COMFORT II, the follow-up was at a median time of 3 years.